Literature DB >> 17048113

Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease.

Mitsuhiko Moriyama1, Hiroshi Matsumura, Akiko Fukushima, Kenji Ohkido, Yasuo Arakawa, Kazushige Nirei, Hiroaki Yamagami, Miki Kaneko, Naohide Tanaka, Yasuyuki Arakawa.   

Abstract

We evaluated zinc concentrations in patients with hepatitis C virus (HCV)-positive chronic liver disease and correlated them with the clinical profiles of the patients. A total of 100 patients with chronic hepatitis (CH), 29 with liver cirrhosis (LC), and 6 who were asymptomatic HCV carriers (ASC) were examined. All of the patients were positive for serum HCV RNA. One hundred eighteen HCV antibody-positive hepatocellear carcinoma (HCC) patients and 11 healthy subjects also were included in this study. Serum zinc concentrations were evaluated using conventional atomic absorption spectrometry. The median concentration of zinc in patients with CH was statistically lower than that in healthy control subjects. The median zinc concentrations of the LC and HCC groups were significantly lower than that of the CH group. A significant correlation was observed between the zinc concentrations and the platelet counts and albumin concentrations. The zinc concentrations did not correlate with tumor size and number and decreased with the development of Child-Pugh stage. The cumulative survival rate after therapy for HCC nodules in the low zinc concentration group was significantly lower than in the high group. We conclude that the serum concentration of zinc influences the clinical profiles in patients with C-viral chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17048113     DOI: 10.1007/s10620-005-9051-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Iron, copper and zinc levels in serum and cirrhotic liver of patients with and without hepatocellular carcinoma.

Authors:  N Nagasue; H Kolno; Y C Chang; T Nakamura
Journal:  Oncology       Date:  1989       Impact factor: 2.935

2.  Inhibitory effect of polaprezinc on the inflammatory response to Helicobacter pylori.

Authors:  Osamu Handa; Norimasa Yoshida; Yukiko Tanaka; Miho Ueda; Takeshi Ishikawa; Tomohisa Takagi; Naoyuki Matsumoto; Yuji Naito; Toshikazu Yoshikawa
Journal:  Can J Gastroenterol       Date:  2002-11       Impact factor: 3.522

3.  Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy.

Authors:  Mitsuhiko Moriyama; Hiroshi Matsumura; Hiroshi Aoki; Toshihiro Shimizu; Kazuhiko Nakai; Takahide Saito; Hiroaki Yamagami; Atsuo Shioda; Miki Kaneko; Iori Goto; Naohide Tanaka; Yasuyuki Arakawa
Journal:  Intervirology       Date:  2003       Impact factor: 1.763

4.  Zinc transport by transferrin in rat portal blood plasma.

Authors:  G W Evans; T W Winter
Journal:  Biochem Biophys Res Commun       Date:  1975-10-27       Impact factor: 3.575

5.  Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C.

Authors:  H Takagi; T Nagamine; T Abe; H Takayama; K Sato; T Otsuka; S Kakizaki; Y Hashimoto; T Matsumoto; A Kojima; J Takezawa; K Suzuki; S Sato; M Mori
Journal:  J Viral Hepat       Date:  2001-09       Impact factor: 3.728

6.  The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme.

Authors:  M Stempniak; Z Hostomska; B R Nodes; Z Hostomsky
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.

Authors:  R A Love; H E Parge; J A Wickersham; Z Hostomsky; N Habuka; E W Moomaw; T Adachi; Z Hostomska
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

8.  Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto.

Authors:  I Levy; M Sherman
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

9.  Relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effect of zinc administration.

Authors:  J Camps; T Bargallo; A Gimenez; S Alie; J Caballeria; A Pares; J Joven; L Masana; J Rodes
Journal:  Clin Sci (Lond)       Date:  1992-12       Impact factor: 6.124

10.  Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis.

Authors:  O Riggio; M Merli; L Capocaccia; M Caschera; A Zullo; G Pinto; E Gaudio; A Franchitto; R Spagnoli; E D'Aquilino
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

View more
  11 in total

Review 1.  The status of zinc in the development of hepatocellular cancer: an important, but neglected, clinically established relationship.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

2.  Insulin resistance derived from zinc deficiency in non-diabetic patients with chronic hepatitis C.

Authors:  Takashi Himoto; Hirohito Yoneyama; Akihiro Deguch; Kazutaka Kurokohchi; Michio Inukai; Hisashi Masugata; Fuminori Goda; Shoichi Senda; Seishiro Watanabe; Satoru Kubota; Shigeki Kuriyama; Tsutomu Masaki
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

Review 3.  Viral hepatocarcinogenesis.

Authors:  W-L Tsai; R T Chung
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

Review 4.  Can zinc enhance response interferon therapy for patients with HCV-related liver disease?

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

5.  Additive Effects of Zinc Chloride on the Suppression of Hepatitis A Virus Replication by Interferon in Human Hepatoma Huh7 Cells.

Authors:  Tatsuo Kanda; Reina Sasaki; Ryota Masuzaki; Hiroshi Takahashi; Mariko Fujisawa; Naoki Matsumoto; Hiroaki Okamoto; Mitsuhiko Moriyama
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

6.  Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection.

Authors:  Yi-Ling Ko; Daisuke Morihara; Kumiko Shibata; Ryo Yamauchi; Hiromi Fukuda; Hideo Kunimoto; Kazuhide Takata; Takashi Tanaka; Shinjiro Inomata; Keiji Yokoyama; Yasuaki Takeyama; Satoshi Shakado; Shotaro Sakisaka
Journal:  Nutrients       Date:  2018-11-02       Impact factor: 5.717

7.  Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C.

Authors:  Hiroshi Matsumura; Kazushige Nirei; Hitomi Nakamura; Yasuo Arakawa; Teruhisa Higuchi; Jyunpei Hayashi; Hiroaki Yamagami; Syunichi Matsuoka; Masahiro Ogawa; Noriko Nakajima; Naohide Tanaka; Mitsuhiko Moriyama
Journal:  J Clin Biochem Nutr       Date:  2012-08-10       Impact factor: 3.114

8.  Plasma zinc level in hepatitis C patients with or without Beta thalassemia major; is there any difference?

Authors:  Mohammad Abbasinazari; Bita Behnava; Yunes Panahi; Azita Hajhossein Talasaz; Shima Salimi; Maryam Keshvari; Leila Mehrnoush; Pegah Karim Elizee; Mohammad Gholami Fesharaki; Mansour Asgharinia; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2013-08-12       Impact factor: 0.660

Review 9.  Associations between Zinc Deficiency and Metabolic Abnormalities in Patients with Chronic Liver Disease.

Authors:  Takashi Himoto; Tsutomu Masaki
Journal:  Nutrients       Date:  2018-01-14       Impact factor: 5.717

Review 10.  Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases.

Authors:  Takashi Himoto; Tsutomu Masaki
Journal:  Nutrients       Date:  2020-07-14       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.